Late onset hypogonadism is defined as clinical and biochemical syndrome characterized by older age, set of typical symptoms, and deficiency in serum testosterone levels.
The quality of life may be decreased and multiple organ systems may be adversely affected.
Prior to the start of testosterone substitution, there should be confirmation of low serum testosterone and a confirmation of need based on clinical findings.
Only if the potential benefit exceeds the risk, then replacement testosterone should be started.
Hypogonadal men with type 2 diabetes are highly likely to have higher bone mass density (BMD), poorer bone geometry and relatively suppressed bone turnover compared with their nondiabetic counterparts, a study has shown.
Treatment with testosterone solution 2 percent (T-sol) for 6 months was generally well tolerated and did not show new safety concerns, according to a study. In addition, the outcomes of low sex drive and low energy indicated further improvement after the double-blind phase.
Testosterone replacement therapy (TRT) in hypogonadal men was associated with a lower cardiovascular (CV) risk, according to a presentation at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore, allaying concerns about the safety of TRT amidst controversial findings from previous studies.
Long-term testosterone replacement therapy (TRT) is beneficial in men with late-onset hypogonadism (LOH) in a study and is even associated with improvement in sexual function and vitality, physical pain, general health, and overall health-related quality of life (HRQoL).
The types of bariatric surgery differentially affect the risk of developing acute pancreatitis postoperatively, such that the risk is greater in patients who undergo vertical sleeve gastrectomy vs Roux-en-Y gastric bypass surgery, according to a study. Risk factors include younger age and presence of gallstones.
An adjuvant trastuzumab treatment course shortened to 9 weeks has failed to demonstrate noninferiority to the standard 1-year course in terms of disease-free survival in breast cancer patients, although the shortened course confers benefits for the risk of severe cardiac toxicity, according to the results of the phase III randomized Short-HER study.